Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension

Author(s):  

Issue:  May/Jun 2018 - Volume 22, Number 3
View All Articles in Issue

Page(s):  263

Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Page 1

Download in electronic PDF format for $75

Abstract:  Erratum for Allen LV Jr. Lansoprazole 3-mg/mL oral suspension. IJPC 2010; 14(3): 246.

Related Keywords: erratum, formulation, lansoprazole

Related Categories: FORMULATIONS, GASTROENTEROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension
May/Jun 2018
Pg. 263

Lansoprazole 3-mg/mL Oral Suspension
Allen Loyd V Jr
May/Jun 2010
Pg. 246

Lansoprazole 3-mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
Sep/Oct 2022
Pg. 429

Lansoprazole 3-mg/mL Oral Liquid
Allen Loyd V Jr
Jan/Feb 2007
Pg. 74

Basics of Compounding for Cough
Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Erratum: Stability of Venlafaxine Immediate-Release Suspensions
Allen Loyd V Jr
Mar/Apr 2011
Pg. 175

Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration
Trissel Lawrence A
, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S
Jul/Aug 2001
Pg. 314-319

Erratum: Zur E. Topical Treatment of Primary Focal Hyperhidrosis, Part 2. IJPC 2019; 23(2):94-104.
Jul/Aug 2019
Pg. 351

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Nitazoxanide 10-mg/mL Oral Suspension
Allen Loyd V Jr
Sep/Oct 2023
Pg. 420

Pediatric Oral Formulations: A Continual Challenge
Hurtado Josephine
, Moffett Brady S
Jan/Feb 2007
Pg. 17-19

Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Allen Loyd V Jr
Jan/Feb 2021
Pg. 43

Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students
Benischek Rita
Mar/Apr 2017
Pg. 105-108

Nimodipine 3-mg/mL Oral Solution
Allen Loyd V Jr
Sep/Oct 2015
Pg. 407

Erratum: Allen LV Jr. Lidocaine hydrochloride 2%, misoprostol 0.0024%, and phenytoin 2% topical wound powder. IJPC 2004; 8(4): 298
Allen Loyd V Jr
Mar/Apr 2006
Pg. 82

Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B
, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
Sep/Oct 2005
Pg. 402-406

Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
Jan/Feb 2021
Pg. 44

Return to Top